Target: BP™ Initiative Helps More Than 9M Americans with Hypertension

Translate to Spanish or other 102 languages!

At a time when uncontrolled hypertension is rising in the United States, the American Heart Association and American Medical Association (AMA) are nationally recognizing 1,812 health care organizations—103 more than in 2023—for efforts to prioritize control of their patients’ blood pressure (BP).  Image for illustration purposes
At a time when uncontrolled hypertension is rising in the United States, the American Heart Association and American Medical Association (AMA) are nationally recognizing 1,812 health care organizations—103 more than in 2023—for efforts to prioritize control of their patients’ blood pressure (BP).  Image for illustration purposes
- Advertisement -

American Medical Association

DALLAS, Texas – At a time when uncontrolled hypertension is rising in the United States, the American Heart Association and American Medical Association (AMA) are nationally recognizing 1,812 health care organizations—103 more than in 2023—for efforts to prioritize control of their patients’ blood pressure (BP). 

Hypertension, or high blood pressure, is a leading preventable risk factor for heart disease, stroke and premature death. According to the 2024 American Heart Association Statistical Update, nearly half of U.S. adults—122.4 million—are living with high BP. High BP accounts for more than $52 billion in annual health care costs1

- Advertisement -

Target: BP™ is a national initiative created in 2015 by the American Heart Association and American Medical Association in response to the high prevalence of uncontrolled blood pressure. Together, the associations:

  • leverage American Heart Association science and the evidence-based AMA MAP™ framework to help care teams organize their approach to providing evidence-based care;
  • assist and support health care organizations to improve and sustain BP control with professional education, practice tools and resources, including support through the associations’ quality improvement programs; and
  • recognize organizations annually with achievement awards celebrating commitment to improvement, adoption of evidence-based BP care and achieving BP control rates of 70% or greater among their patients. 

The organizations participating in Target: BP this year represent 47 states or U.S. territories and serve more than 34 million patients, including 9 million people with hypertension. Nearly half of participating organizations are nonprofit health centers that receive federal funding to reach medically underserved populations, known as federally qualified health centers, reflecting the associations’ shared commitment to improving health equity.

Among those organizations recognized for their efforts, more than half achieved Gold or Gold+ award level recognition, which requires BP control rates of greater than or equal to 70%. About 41% of awardees achieved Silver recognition, which requires BP control data to be submitted and 4 out of 6 evidence-based BP activities to be completed. The remainder received Participation-level recognition for submitting data for the first time and committing to reducing the number of adult patients with uncontrolled BP.

“High BP is a ‘silent killer,’ often presenting no obvious symptoms,” said Keith Churchwell, M.D., FAHA, American Heart Association volunteer president, associate clinical professor of medicine at Yale School of Medicine and adjunct associate professor of medicine at the Vanderbilt School of Medicine. “Programs like Target: BP help health care organizations and care teams work to close gaps in hypertension control through patient awareness and education on managing risk factors, such as lifestyle choices and family history, and improving overall well-being.”

- Advertisement -

Since the American Heart Association and American Medical Association launched Target: BP™ in 2017, more than 4,150 health care organizations have joined the nationwide movement to make heart health a priority — sharing a common goal to improve health outcomes associated with heart disease, the No. 1 killer in the U.S.

“With the high prevalence of uncontrolled blood pressure in the U.S., it is imperative that all Americans have access to quality health care, and that all physicians and care teams have the tools they need, to help patients better control their high blood pressure,” said AMA President Bruce A. Scott, M.D. “We must collectively work to improve blood pressure control and reduce the burden of cardiovascular disease to improve the health our nation.”

New award levels and criteria will be launched in 2025, including a new Silver+ award level and new criteria for Silver+ and Gold+ awards. 

More information about Target: BP can be found at TargetBP.org and a list of recognized organizations can be found here (PDF). 

Additional Resources: 


1Table 8-1. Heart Disease and Stroke Statistics—2024 Update: A Report From the American Heart Association. Circulation. 2024;149:e347-e913. https://www.ahajournals.org/doi/epub/10.1161/CIR.0000000000001209.

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

DHR Health To Add Advanced Vascular Care Services to Its Brownsville Multispecialty Clinic

Beginning August 31, 2026, patients living in the lower Rio Grande Valley, will have access to advanced vascular surgical services at the DHR Health Brownsville Multispecialty Clinic, located next to its hospital, DHR Health Brownsville, at 4770 N. Expressway.

CDC Issues Warning Over Multistate Salmonella Outbreak Linked to Jalapeños

The Centers for Disease Control and Prevention (CDC) has issued a food safety alert following a multistate outbreak of Salmonella infections linked to contaminated jalapeño peppers

ER 24/7 Brownsville – Grand Opening & Ribbon Cutting Ceremony, Aug. 6th

The Brownsville Chamber of Commerce and its Bienvenidos Committee are excited to announce the Grand Opening of ER 24/7 Brownsville today, August 6, 2026, at 3:00 PM. This celebration will take place at 449 E. Alton Gloor Blvd in Brownsville, Texas. 

New Blood Test Spots Early Signs of Immunotherapy Effectiveness

Researchers at the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy determined that liquid biopsy—a blood test that detects circulating tumor DNA (ctDNA)—can predict, within a few weeks, whether patients with advanced non-small cell lung cancer are benefiting from immunotherapy.
- Advertisement -